← Eichor
Condition: Gmg Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gmg

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Phase N/A · 12 location(s) · AstraZeneca · NCT06909253Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myast
Phase 3 · 145 location(s) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of M · NCT06463587A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 9 location(s) · UCB Biopharma SRL · NCT06055959ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With
Phase 2 · 15 location(s) · argenx · NCT07284420A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Disease
Phase 1 · 13 location(s) · Arcellx, Inc. · NCT06626919Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Phase N/A · 7 location(s) · Alexion Pharmaceuticals, Inc. · NCT06312644PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 · 13 location(s) · Alexion Pharmaceuticals, Inc. · NCT06607627A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Gener
Phase 3 · 129 location(s) · Novartis Pharmaceuticals · NCT06744920Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni
Phase 4 · 12 location(s) · UCB Biopharma SRL · NCT07246564Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Phase N/A · 51 location(s) · Alexion Pharmaceuticals, Inc. · NCT04202341ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip
Phase N/A · 18 location(s) · argenx · NCT07294170Zilucoplan for Severe gMG Exacerbations
Phase 3 · 1 location(s) · Miriam Freimer · NCT07215949GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07058298A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Ag
Phase 3 · 125 location(s) · Novartis Pharmaceuticals · NCT06517758A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen
Phase 2 · 4 location(s) · Amgen · NCT06987539ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Pa
Phase 2 · 2 location(s) · argenx · NCT07673627A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasth
Phase N/A · 30 location(s) · argenx · NCT07595653Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT07411963A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Phase 4 · 12 location(s) · Alexion Pharmaceuticals, Inc. · NCT07221838A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis
Phase 4 · 18 location(s) · argenx · NCT06909214Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Phase N/A · 7 location(s) · AstraZeneca · NCT07247279Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07215650A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms
Phase 1 · 35 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06220201A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Phase 3 · 111 location(s) · Vor Biopharma · NCT06456580
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.